Investors & Media

Investors & Media

Investors

About Be the Match BioTherapies

Magenta and Be The Match BioTherapies have initiated a collaboration to support their shared goals of improving transplant medicine. Magenta and Be The Match BioTherapies will explore opportunities to work together across all of Magenta’s research efforts, from discovery through clinical development. Under this agreement, Magenta may leverage Be The Match BioTherapies’ capabilities, including its cell therapy delivery platform, industry relationships, clinical trial design and management, and patient outcomes data derived from the NMDP/Be The Match, which operates the largest and most diverse marrow registry in the world. NMDP/Be The Match has a network of more than 486 organizations that support marrow transplant worldwide, including 178 transplant centers in the United States and more than 45 international donor centers and cooperative registries.

Press Releases

June 20, 2018
Magenta Therapeutics Announces Pricing of Initial Public Offering

April 9, 2018
Magenta Therapeutics Secures $52 Million in Series C Financing

April 6, 2018
Magenta Therapeutics Appoints Amy Ronneberg, President of Be The Match BioTherapies, to Board of Directors

April 5, 2018
Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders

View All Press Releases

Media Contacts

For media inquiries, please contact:
Manisha Pai, Vice President of Communications and Investor Relations
mpai@magentatx.com

Social Media

Twitter
LinkedIn

Awards